Dyslipidaemia, hypercoagulability and the metabolic syndrome

Current Vascular Pharmacology

Volumn 4, Issue 3, 2006, Pages 175-183

  Kakafika, Anna I ^a   Liberopoulos, Evagelos N ^b   Karagiannis, Asterios ^c   Athyros, Vasilios G ^c   Mikhailidis, Dimitri P ^a,d  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF IOANNINA   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Coagulation; Dyslipidaemia; Free fatty acids; High density lipoprotein; Insulin resistance; Metabolic syndrome; Obesity; Triglycerides

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; APOLIPOPROTEIN B; BLOOD CLOTTING FACTOR 8; C REACTIVE PROTEIN; FATTY ACID; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; SIBUTRAMINE; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; VON WILLEBRAND FACTOR; ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; AUTACOID; BLOOD CLOTTING FACTOR 7; CLOFIBRIC ACID; FIBRINOLYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; SERPINE1 PROTEIN, HUMAN;

BLOOD CLOTTING; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; DISEASE PREDISPOSITION; DYSLIPIDEMIA; HEREDITY; HUMAN; HYPERCOAGULABILITY; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; OBESITY; PHYSICAL ACTIVITY; REVIEW; RISK FACTOR; RISK REDUCTION; WEIGHT REDUCTION; ADIPOSE TISSUE; ANIMAL; BLOOD; CARDIOVASCULAR DISEASE; LIFESTYLE; METABOLISM; THROMBOPHILIA;

ADIPOSE TISSUE; ADIPOSITY; ANIMALS; ANTILIPEMIC AGENTS; ASPIRIN; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CLOFIBRIC ACID; DYSLIPIDEMIAS; FACTOR VII; FIBRINOLYTIC AGENTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; LIFE STYLE; LIPOPROTEINS, LDL; METABOLIC SYNDROME X; OBESITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBOPHILIA; TRIGLYCERIDES; VON WILLEBRAND FACTOR;

EID: 33747855564     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016106777698432     Document Type: Review

References (141)

1. Caglayan E, Blaschke F, Takata Y, Hsueh WA. Metabolic syndrome-interdependence of the cardiovascular and metabolic pathways. Curr Opin Pharmacol 2005; 5: 135-42.
2. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-9.
3. Athyros VG, Mikhailidis DP, Papageorgiou AA, Didangelos TP, Ganotakis ES, Symeonidis AN. Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study. Curr Med Res Opin 2004; 20: 1691-701.
4. Grundy SM, Hansen B, Smith SC, Cleeman JI, Kahn RA, American Heart Association. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Arterioscler Thromb Vasc Biol 2004; 24: e19-24.
5. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433-8.
6. McFarlane S, Banerji. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001; 86: 713-8.
7. Sowers JR. Recommendations for special populations: diabetes mellitus and the metabolic syndrome. Am J Hypertens 2003; 16: 41S-45S.
8. Devaraj S, Rosenson RR, Jialal I. Metabolic syndrome: an appraisal of the pro-inflammatory and procoagulant status. Endocrinol Metab Clin North Am 2004; 33: 431-53.
9. Coppack SW. Pro-inflammatory cytokines and adipose tissue. Proc Nutr Soc 2001; 60: 349-56.
10. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7: 941-6.
11. Lindsay R, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet 2002; 360: 57-8.
12. Tan KC, Xu A, Chow WS, Lam MC, Ai VH, Tam SC, et al. Hypoadiponectinemia is associated with impaired endotheliumdependent vasodilation. J Clin Endocrinol Metab 2004; 89: 765-9.
13. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-5.
14. Paraskevas KI, Liapis CD, Mikhailidis DP. Leptin: A promising therapeutic target with pleiotropic action besides body weight regulation. Curr Drug Targets 2006; In press.
15. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607.
16. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 1992; 41: 715-22.
17. Groop LC. Insulin resistance: the fundamental trigger of type 2 diabetes. Diabetes Obes Metab 1999; (Suppl 1): S1-S7.
18. Abbasi F, Brown BWJr, Lamendola C, McLaughlin T, Reaven GM. Relationship between obesity, insulin resistance, and coronary heart disease risk. J Am Coll Cardiol 2002; 40: 937-43.
19. Flatt JP. Importance of nutrient balance in body weight regulation. Diabetes Metab Rev 1988; 4: 571-81.
20. Arner P. Control of lipolysis and its relevance to development of obesity in man. Diabetes Metab Rev 1988; 4: 507-15.
21. Felig P. Insulin is the mediator of feeding-related thermogenesis: insulin resistance and/or deficiency results in a thermogenic defect which contributes to the pathogenesis of obesity. Clin Physiol 1984; 4: 267-73.
22. Kolovou GD, Anagnostopoulou K, Cokkinos DV. Pathophysiology of dyslipidaemia in the metabolic syndrome. Postgrad Med J 2005; 81: 358-66.
23. Ginsberg HN, Huang LS. The insulin resistance syndrome: impact on lipoprotein metabolism and atherothrombosis. J Cardiovasc Risk 2000; 7: 325-31.
24. Ginsberg HN. Treatment for patients with the metabolic syndrome. Am J Cardiol 2003; 91: 29-39.
25. Saleh J, Sniderman AD, Cianflone K. Regulation of plasma fatty acid metabolism. Clin Chim Acta 1999; 286: 163-80.
26. Facchini FS, Hollenbeck CB, Jeppensen J, Chen YD, Reaven GM. Insulin resistance and cigarette smoking. Lancet 1992; 339: 1128-30.
27. Lee WY, Jung CH, Park JS, Rhee EJ, Kim SW. Effects of smoking, alcohol, exercise, education, and family history on the metabolic syndrome as defined by the ATP III. Diabetes Res Clin Pract 2005; 67: 70-7.
28. Cryer PE, Haymond MW, Santiago JV, Shah SD. Norepinephrine and epinephrine release and adrenergic mediation of smoking-associated hemodynamic and metabolic events. N Engl J Med 1976; 295: 573-7.
29. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest 2000; 106: 453-8.
30. Barter P. The realities of dyslipidaemia in metabolic syndrome and diabetes. Br J Diabetes Vasc Dis 2005; 5 (suppl 1): S7-S11.
31. Morton RE. Cholesteryl ester transfer protein and its plasma regulator: lipid transfer inhibitor protein. Curr Opin Lipidol 1999; 10: 321-7.
32. Arai T, Yamashita S, Hirano K. Increased plasma cholesteryl ester transfer protein in obese subjects: a possible mechanism for the reduction of serum HDL cholesterol levels in obesity. Arterioscler Thromb 1994; 14: 1129-36.
33. Reilly MP, Rader DJ. The metabolic syndrome: more than the sum of its parts? Circulation 2003; 108: 1546-51.
34. Kolovou G, Mikhailidis DP, Anagnostopoulou K, Daskalopoulou S, Cokkinos DV. Tangier Disease: a reflection of the importance of HDL. Curr Med Chem 2006; In press.
35. Wang Y, Kurdi-Haidar B, Oram JF. LXR-mediated activation of macrophage stearoyl-CoA desaturase generates unsaturated fatty acids that destabilize ABCA1. J Lipid Res 2004; 45: 972-80.
36. Kolovou GD, Daskalova DC, Petropoulos II, Anagnostopoulou KK, Bilianou HI, Pilatis ND, et al. Effect of baseline levels on response of high-density lipoprotein cholesterol to hypolipidemic treatment. Am J Cardiol 2003; 92: 1339-42.
37. Robins SJ. Targeting low high-density lipoprotein cholesterol for therapy: lessons from the Veterans Affairs High-density Lipoprotein Intervention Trial. Am J Cardiol 2001; 88: 19N-23N.
38. Nesto RW. Beyond low-density lipoprotein: addressing the atherogenic lipid trad in type 2 diabetes mellitus and the metabolic syndrome. Am J Cardiovasc Drugs 2005; 5: 379-87.
39. Packard CJ. Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. Biochem Soc Trans 2003; 31: 1066-9.
40. Lamarche B, Tchernof A, Mauriege P, Cantin B, Dagenais GR, Lupien PJ, et al. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998; 279: 1955-61.
41. Dobiasova M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem 2001; 34: 583-8.
42. Solymoss BC, Bourassa MG, Campeau L, Sniderman A, Marcil M, Lesperance J, et al. Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity. Am J Cardiol 2004; 93: 159-64.
43. Kwiterovich PO Jr. Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity. Am J Cardiol 2002; 90: 30-47i.
44. Kwiterovich PO Jr, Coresh J, Bachorik PS. Prevalence of hyperapo-betalipoproteinemia and other lipoprotein phenotypes in men (aged < or =50 years) and women (< or =60 years) with coronary artery disease. Am J Cardiol 1993; 71: 631-9.
45. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infraction (AMORIS study): a prospective study. Lancet 2001; 358: 2026-33.
46. Sniderman AD, Scantlebury T, Cianflone K. Hypertriglyceridemic hyperapob: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus. Intern Med 2001; 135: 447-59.
47. Pirro M, Mauriege P, Tchernof A, Cantin B, Dagenais GR, Despres JP. Plasma free fatty acid levels and the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Atherosclerosis 2002; 160: 377-84.
48. Ginsberg HN, Illingworth DR. Postprandial dyslipidemia: an atherogenic disorder common in patients with diabetes mellitus. Am J Cardiol 2001; 88: 9H-15H.
49. Kolovou GD, Daskalova DC, Iraklianou SA, Adamopoulou EN, Pilatis ND, Hatzigeorgiou GC, et al. Postprandial lipemia in hypertension. J Am Coll Nutr 2003; 22: 80-7.
50. Mazzone T, Foster D, Chait A. In vivo stimulation of low-density lipoprotein degradation by insulin. Diabetes 1984; 33: 333-8.
51. Cummings MH, Watts GF, Umpleby AM, Hennessy TR, Kelly JM, Jackson NC, et al. Acute hyperinsulinemia decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM. Diabetes 1995; 44: 1059-65.
52. Cooper AD. Hepatic uptake of chylomicron remnants. J Lipid Res 1997; 38: 2173-92.
53. James AP, Watts GF, Barrett PH, Smith D, Pal S, Chan DC, et al. Effect of weight loss on postprandial lipemia and low-density lipoproteinreceptor binding in overweight men. Metabolism 2003; 52: 136-41.
54. English PJ, Coughlin SR, Hayden K, Malik IA, Wilding JP. Plasma adiponectin increases postprandially in obese, but not in lean, subjects. Obes Res 2003; 11: 839-44.
55. Yudkin JS. Abnormalities of coagulation and fibrinolysis in insulin resistance. Evidence for a common antecedent? Diabetes Care 1999; 22 Suppl 3: C25-C30.
56. Meigs JB, Mittleman MA, Nathan DM, Tofler GH, Singer DE, Murphy-Sheehy PM, et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis. JAMA 2000; 283: 221-8.
57. Nieuwdorp M, Stroes ES, Meijers JC, Buller H. Hypercoagulability in the metabolic syndrome. Curr Opin Pharmacol 2005; 5: 155-9.
58. Mertens I, Van Gaal LF. Obesity, haemostasis and the fibrinolytic system. Obes Rev 2002; 3: 85-101.
59. Juhan-Vague I, Vague P. Hypofibrinolysis and insulin-resistance. Diabete Metab 1991; 17: 96-100.
60. Lijnen HR, Collen D. Mechanisms of physiological fibrinolysis. Baillieres Clin Haematol 1995; 8: 277-90.
61. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999; 107: 450-5.
62. Li XN, Grenett HE, Benza RL, Demissie S, Brown SL, Tabengwa EM, et al. Genotype-specific transcriptional regulation of PAI-1 expression by hypertriglyceridemic VLDL and Lp(a) in cultured human endothelial cells. Arterioscler Thromb Vasc Biol 1997; 17: 3215-23.
63. Mussoni L, Mannucci L, Sirtori M, Camera M, Maderna P, Sironi L, et al. Hypertriglyceridemia and regulation of fibrinolytic activity. Arterioscler Thromb 2006; 12: 19-27.
64. Latron Y, Chautan M, Anfosso F, Alessi MC, Nalbone G, Lafont H, et al. Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor-1 synthesis by endothelial cells. Arterioscler Thromb 1991; 11: 1821-9.
65. Calles-Escandon J, Mirza SA, Sobel BE, Schneider DJ. Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects. Diabetes 1998; 47: 293.
66. Andersen P, Seljeflot I, Abdelnoor M, Arnesen H, Dale PO, Lovik A, et al. Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome. Metabolism 1995; 44: 611-6.
67. Velasquez EM, Mendoza SG, Wang P, Glueck CJ. Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein [a], and immunoreactive insulin levels in patients with polycystic ovary syndrome. Metabolism 1997; 46: 454-7.
68. Kruszynska YT, Yu JC, Olefsky JM, Sobel BE. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and lean and obese normal subjects. Diabetes 2000; 49: 633-9.
69. Alessi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 1997; 46: 860-7.
70. Cigolini M, Tonoli M, Borgato L, Frigotto L, Manzato F, Zeminian S, et al. Expression of plasminogen activator inhibitor-1 in human adipose tissue: a role for TNF-alpha? Atherosclerosis 1999; 143: 81-90.
71. Birgel M, Gottschling-Zeller H, Rohrig K, Hauner H. Role of cytokines in the regulation of plasminogen activator inhibitor-1 expression and secretion in newly differentiated subcutaneous human adipocytes. Arterioscler Thromb Vasc Biol 2000; 20: 1682-7.
72. Juhan-Vague I. Haemostatic parameters and vascular risk. Atherosclerosis 1996; 124: S49-S55.
73. Balleisen L, Assmann G, Bailey J, Epping PH, Schulte H, van de Loo J. Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population: I. Baseline data on the relation to age, gender, body-weight, smoking, alcohol, pill-using, and menopause. Thromb Haemost 1985; 54: 475-9.
74. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, et al. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-7.
75. Meilahn EN, Cauley JA, Tracy RP, Macy EO, Gutai JP, Kuller LH. Association of sex hormones and adiposity with plasma levels of fibrinogen and PAI-1 in postmenopausal women. Am J Epidemiol 1996; 143: 159-66.
76. Rosenson RS, Lowe GD. Effects of lipids and lipoproteins on thrombosis and rheology. Atherosclerosis 1998; 140: 271-80.
77. Wannamethee SG, Lowe GD, Shaper AG, Rumley A, Lennon L, Whincup PH. The metabolic syndrome and insulin resistance: relationship to haemostatic and inflammatory markers in older non-diabetic men. Atherosclerosis 2005; 181: 101-8.
78. Marckmann P, Toubro S, Astrup A. Sustained improvement in blood lipids, coagulation, and fibrinolysis after major weight loss in obese subjects. Eur J Clin Nutr 1998; 52: 329-33.
79. Slabber M, Barnard HC, Kuyl JM, Badenhorst CJ. Effect of a short-term very low calorie diet on plasma lipids, fibrinogen, and factor VII in obese subjects. Clin Biochem 1992; 25: 334-5.
80. Folsom AR, Qamhieh HT, Wing RR, Jeffery RW, Stinson VL, Kuller LH, et al. Impact of weight loss on plasminogen activator inhibitor [PAI-1], factor VII, and other hemostatic factors in moderately overweight adults. Arterioscler Thromb 1993; 13: 162-9.
81. Ford ES. The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey. Atherosclerosis 2003; 168: 351-8.
82. Conlan MG, Folsom AR, Finch A, Davis CE, Sorlie P, Marcucci G, et al. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost 1993; 70: 380-5.
83. Juhan-Vague I, Thompson SG, Jespersen J. Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. The ECAT Angina Pectoris Study Group. Arterioscler Thromb 1993; 13: 1865-73.
84. Cushman M, Yanez D, Psaty BM, Fried LP, Heiss G, Lee M, et al. Association of fibrinogen and coagulation factors VII and VIII with cardiovascular risk factors in the elderly: the Cardiovascular Health Study. Cardiovascular Health Study Investigators. Am J Epidemiol 1996; 143: 665-76.
85. Charles MA, Morange P, Eschwege E, Andre P, Vague P, Juhan-Vague I. Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity..Diabetes Care 1998; 21: 1967-72.
86. De Pergola G, De Mitrio V, Giorgino F, Sciaraffia M, Minnena A, Di Bari L, et al. Increase in both pro-thrombotic and antithrombotic factors in obese premenopausal women: relationship with body fat distribution. Int J Obes Relat Metab Disord 1997; 21: 527-35.
87. Georgieva AM, Cate HT, Keulen ET, Van Oerle R, Govers-Riemslag JW, Hamulyak K, et al. Prothrombotic markers in familial combined hyperlipidemia: evidence of endothelial cell activation and relation to metabolic syndrome. Atherosclerosis 2004; 175: 345-51.
88. Deedwania PC. Mechanisms of endothelial dysfunction in the metabolic syndrome. Curr Diab Rep 2003; 3: 289-92.
89. Barradas MA, Mikhailidis DP, Dandona P. The effect of nonesterified fatty acids on vascular ADP-degrading enzyme activity. Diabetes Res Clin Pract 1987; 3: 9-19.
90. Steinberg HO, Baron AD. Vascular function, insulin resistance and fatty acids. Diabetologia 2001; 45: 623-34.
91. Scott CL. Diagnosis, prevention, and intervention for the metabolic syndrome. Am J Cardiol 2003; 92: 35i-42i.
92. Baron AD. Vascular reactivity. Am J Cardiol 1999; 84: 25J-7J.
93. Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest 1994; 94: 1172-9.
94. Trovati M, Mularoni EM, Burzacca S, Ponziani MC, Massucco P, Mattiello L, et al. Impaired insulin-induced platelet antiaggregating effect in obesity and in obese NIDDM patients. Diabetes 1995; 44: 1318-22.
95. Doggen CJ, Smith NL, Lemaitre RN, Heckbert SR, Rosendaal FR, Psaty BM. Serum lipid levels and the risk of venous thrombosis. Arterioscler Thromb Vasc Biol 2004; 24: 1970-5.
96. Englyst NA, Taube JM, Aitman TJ, Baglin TP, Byrne CD. A novel role for CD36 in VLDL-enhanced platelet activation. Diabetes 2003; 52: 1248-55.
97. Jarvis GE, Atkinson BT, Snell DC, Watson SP. Distinct roles of GPVI and integrin alpha(2)beta(1) in platelet shape change and aggregation induced by different collagens. Br J Pharmacol 2002; 137: 107-17.
98. Gertow K, Pietilainen KH, Yki-Jarvinen H, Kaprio J, Rissanen A, Eriksson P, et al. Expression of fatty-acid-handling proteins in human adipose tissue in relation to obesity and insulin resistance. Diabetologia 2004; 47: 1118-25.
99. Avellone G, Di Garbo V, Cordova R, Raneli G, De Simone R, Bompiani G. Coagulation, fibrinolysis and haemorheology in premenopausal obese women with different body fat distribution. Thromb Res 1994; 75: 223-31.
100. Landin K, Stigendal L, Eriksson P, Krotkiewski M, Risberg B, Tengborn L, et al. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism 1990; 10: 1044-8.
101. Ditschuneit HH, Flechtner-Mors M, Adler G. Fibrinogen in obesity before and after weight reduction. Obes Res 1995; 3: 43-8.
102. Fruhbeck G, Gomez-Ambrosi J, Muruzabal FJ, Burrell MA. The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am J Physiol Endocrinol Metab 2001; 280: E827-47.
103. Primrose JN, Davies JA, Prentice CR, Hughes R, Johnston D. Reduction in factor VII, fibrinogen and plasminogen activator inhibitor-1 activity after surgical treatment of morbid obesity. Thromb Haemost 1992; 68: 396-9.
104. Raynaud E, Perez-Martin A, Brun J, Aissa-Benhaddad A, Fedou C, Mercier J. Relationships between fibrinogen and insulin resistance. Atherosclerosis 2000; 150: 365-70.
105. Coban E, Sari R, Ozdogan M, Akcit F. Levels of plasma fibrinogen and d-dimer in patients with impaired fasting glucose. Exp Clin Endocrinol Diabetes 2005; 113: 35-7.
106. Muntner P, He J, Chen J, Fonseca V, Whelton PK. Prevalence of non-traditional cardiovascular disease risk factors with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: Analysis of the Third National Health and Nutrition Examination Survey (NHANES III). Ann Epidemiol 2004; 14: 686-95.
107. Liberopoulos EN, Mikhailidis DP, Elisaf MS. Diagnosis and management of the metabolic syndrome in obesity. Obes Rev 2005; 6: 283-96.
108. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-50.
109. Daskalopoulou SS, Mikhailidis DP, Elisaf MS. Prevention and treatment of the metabolic syndrome. Angiology 2004; 55: 589-612.
110. Franz MJ, Bantle JP, Beebe CA, Brunzell JD, Chiasson JL, Gorg A, et al. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care 2002; 25: 148-98.
111. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 1992; 16: 397-415.
112. Hecker KD, Kris-Etherton PM, Zhao G, Coval S, St Jeor S. Impact of body weight and weight loss on cardiovascular risk factors. Curr Atheroscler Rep 1999; 1: 236-42.
113. Liberopoulos EN, Tsouli S, Mikhailidis DP, Elisaf MS. Preventing type 2 Diabetes in high risk patients: an overview of lifestyle and pharmacological measures. Curr Drug Targets 2006; 7: 211-280.
114. Snow V, Barry P, Fitterman N, Qaseem A, Weiss K. Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2005; 142: 525-31.
115. Filippatos TD, Kiortsis DN, Liberopoulos EN, Mikhailidis DP, Elisaf MS. A review of the metabolic effects of sibutramine. Curr Med Res Opin 2005; 21: 457-68.
116. Kiortsis D, Filippatos T, Elisaf M. The effects of orlistat on metabolic parameters and other cardiovascular risk factors. Diabete Metab 2005; 31: 15-22.
117. Thompson PDBD, Pina IL, Balady GJ, Williams MA, Marcus BH, Berra K, et al. Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the American Heart Association council on clinical cardiology (subcommittee on exercise, rehabilitation, and prevention) and the council on nutrition, physical activity, and metabolism (subcommittee on physical activity). Circulation 2003; 107: 3109-16.
118. Trichopoulou A, Costacou T, Bamia C, Trichopoulos D. Adherence to a Mediterranean diet and survival in a Greek population. N Engl J Med 2003; 348: 2599-608.
119. Panagiotakos DB, Polychronopoulos E. The role of Mediterranean diet in the epidemiology of metabolic syndrome; converting epidemiology to clinical practice. Lipids Health Dis 2005; 4: 7.
120. Freiberg MS, Cabral HJ, Heeren TC, Vasan RS, Curtis Ellison R. Third National Health and Nutrition Examination Survey. Alcohol consumption and the prevalence of the Metabolic Syndrome in the US: a cross-sectional analysis of data from the Third National Health and Nutrition Examination Survey. Diabetes Care 2004; 27: 2954-9.
121. Leighton F, Miranda-Rottmann S, Urquiaga I. A central role of eNOS in the protective effect of wine against metabolic syndrome. Cell Biochem Funct 2005; [Epub ahead of print].
122. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. National Heart Lung and Blood Institute; American College of Cardiology Foundation; American Heart Association. Circulation 2004; 110: 227-39.
123. Xydakis AM, Ballantyne CM. Management of metabolic syndrome: statins. Endocrinol Metab Clin North Am 2004; 33: 509-23.
124. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-96.
125. Pyorala K, Ballantyne CM, Gumbiner B, Lee MW, Shah A, Davies MJ, et al. Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 2004; 27: 1735-40.
126. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103: 357-62.
127. Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004; 57: 728-34.
128. Athyros VG, Elisaf MS, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, et al. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek atorvastatin and coronary-heart-disease evaluation (GREACE) study. Am J Kidney Dis 2004; 43: 589-99.
129. Wierzbicki AS, Mikhailidis DP, Wray R, Schachter M, Cramb R, Simpson WG, et al. Statin-fibrate combination therapy for hyperlipidaemia: a review. Curr Med Res Opin 2003; 19: 155-68.
130. Mikhailidis DP, Wierzbicki AS, Daskalopoulou S, Al-Saady N, Griffiths H, Hamilton G, et al. The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel. Curr Med Res Opin 2005; 21: 959-69.
131. Daskalopoulou SS, Mikhailidis DP. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with ezetimibe plus simvastatin. Curr Med Res Opin 2006; in press.
132. Farnier M, Freeman MW, Macdonell G, Perevozskaya I, Davies MJ, Mitchel YB, et al. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J 2005; 26: 897-905.
133. Wagh A, Stone NJ. Treatment of metabolic syndrome. Exp Rev Cardiovasc Ther 2004; 2: 213-28.
134. Papadakis JA, Mikhailidis DP, Vrentzos GE, Kalikaki A, Kazakou I, Ganotakis ES. Effect of antihypertensive treatment on plasma fibrinogen and serum HDL levels in patients with essential hypertension. Clin Appl Thromb Hemost 2005; 11: 139-46.
135. Ganotakis ES, Papadakis JA, Vrentzos GE, Mikhailidis DP. The effects of antihypertensive therapy on haemostatic parameters. Curr Pharm Des 2003; 9: 2445-64.
136. Ridker PM, Cannon CP, Morrow D. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 20-8.
137. Rattazzi M, Puato M, Faggin E, Bertipaglia B, Zambon A, Pauletto P. C-reactive protein and inteleukin-6 in vascular disease: culprits or passive bystanders? J Hypertens 2003; 21: 1787-803.
138. Pepys MB. CRP or not CRP? Arterioscler Thromb Vasc Biol 2005; 25: 1091-4.
139. Timpson NJ, Lawlor DA, Harbord RM, Gaunr TR, Day INM, Palmer LJ, et al. C-reactive protein and its role in metabolic syndrome: mendelian randomisation study. Lancet 2005; 366: 1954-9.
140. Balk EM, Lau J, Goudas LC, Jordan HS, Kupelnick B, Kim LU, et al. Effects of Statins on Nonlipid Serum Markers Associated with Cardiovascular disease. Ann Intern Med 2003; 139: 670-82.
141. Tsimihodimos V, Kostoula A, Kakafika A, Bairaktari E, Tselepis AD, Mikhailidis DP, et al. Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values. J Cardiovasc Pharmacol Ther 2004; 9: 27-33.